Toon-Shi

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Asthma2 trials
• COPD2 trials
• Endometrial cancer2 trials
• Lung cancer2 trials
• Ovarian cancer2 trials
• Prostate cancer2 trials
• Alzheimer disease1 trial
• Cervical cancer1 trial
• Childhood cancers1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Liver cirrhosis1 trial

Phase

• Phase 313 trials
• Phase 22 trials

Status

• Active, not recruiting5 trials
• Completed4 trials
• Recruiting4 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca14 trials
• Biogen1 trial

Running trials

• Recruiting

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· Phase 3· AstraZeneca· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

  NCT05221840· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• COPD1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05364931· Phase 2· AstraZeneca· Source

• Completed

  A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

  NCT05202262· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source